1403 related articles for article (PubMed ID: 8721447)
1. CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma.
Fernández-Figueras MT; Ariza A; Calatrava A; Puig L; Fernández-Vasalo A; Ferrándiz C
J Cutan Pathol; 1996 Apr; 23(2):133-9. PubMed ID: 8721447
[TBL] [Abstract][Full Text] [Related]
2. CD44 and variants in melanocytic skin neoplasms.
Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential.
Manten-Horst E; Danen EH; Smit L; Snoek M; Le Poole IC; Van Muijen GN; Pals ST; Ruiter DJ
Int J Cancer; 1995 Jun; 64(3):182-8. PubMed ID: 7542641
[TBL] [Abstract][Full Text] [Related]
4. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
5. CD44 expression in benign and malignant nevomelanocytic lesions.
Leigh CJ; Palechek PL; Knutson JR; McCarthy JB; Cohen MB; Argenyi ZB
Hum Pathol; 1996 Dec; 27(12):1288-94. PubMed ID: 8958300
[TBL] [Abstract][Full Text] [Related]
6. CD44 expression in melanocytic lesions: a marker of malignant progression?
Harwood CA; Green MA; Cook MG
Br J Dermatol; 1996 Dec; 135(6):876-82. PubMed ID: 8977706
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential.
Seelentag WK; Böni R; Günthert U; Futo E; Burg G; Heitz PU; Roth J
J Cutan Pathol; 1997 Apr; 24(4):206-11. PubMed ID: 9138110
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD44 variant isoforms in malignant melanoma.
Seiter S; Schadendorf D; Herrmann K; Schneider M; Rösel M; Arch R; Tilgen W; Zöller M
Clin Cancer Res; 1996 Mar; 2(3):447-56. PubMed ID: 9816190
[TBL] [Abstract][Full Text] [Related]
9. Actin-binding protein expression in benign and malignant melanocytic proliferations.
Bouffard D; Duncan LM; Howard CA; Mihm MC; Byers HR
Hum Pathol; 1994 Jul; 25(7):709-14. PubMed ID: 8026830
[TBL] [Abstract][Full Text] [Related]
10. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
13. CD44 loss in gastric stromal tumors as a prognostic marker.
Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
15. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
16. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
17. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
18. Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma.
Siiskonen H; Poukka M; Tyynelä-Korhonen K; Sironen R; Pasonen-Seppänen S
BMC Cancer; 2013 Apr; 13():181. PubMed ID: 23560496
[TBL] [Abstract][Full Text] [Related]
19. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
20. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
